Advanced search
Publication Cover
Expert Review of Medical Devices Volume 7, 2010 - Issue 1
Submit an article Journal homepage
202
Views
16
CrossRef citations to date
0
Altmetric
Review

Why do some promising brain-stimulation devices fail the next steps of clinical development?

Rodrigo CL Edelmuth Laboratory of Neuromodulation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA and Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA and University City of São Paulo Medical School, São Paulo, Brazil
,
Michael A Nitsche University of Gottingen, Gottingen, Germany
,
Linamara Battistella University of São Paulo, São Paulo, Brazil
&
Felipe Fregni Laboratory of Neuromodulation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA and Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA and 330 Brookline Avenue, KS-158, Boston, MA 02215, USA. [email protected]
Pages 67-97 | Published online: 09 Jan 2014

References

  • Johnston SC, Hauser SL. Neurology and medical devices. Ann. Neurol.60(4), A11–A12 (2006).
  • Lisanby SH, Belmaker RH. Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress. Anxiety12(3), 178–187 (2000).
  • Fregni F, Schachter SC, Pascual-Leone A. Transcranial magnetic stimulation treatment for epilepsy: can it also improve depression and vice versa? Epilepsy Behav.7(2), 182–189 (2005).
  • Wu AD, Fregni F, Simon DK, Deblieck C, Pascual-Leone A. Noninvasive brain stimulation for Parkinson’s disease and dystonia. Neurotherapeutics5(2), 345–361 (2008).
  • Rossi S, Rossini PM. TMS in cognitive plasticity and the potential for rehabilitation. Trends Cogn. Sci.8(6), 273–279 (2004).
  • Bolognini N, Pascual-Leone A, Fregni F. Using non-invasive brain stimulation to augment motor training-induced plasticity. J. Neuroeng. Rehabil.6, 8 (2009).
  • Fregni F, Freedman S, Pascual-Leone A. Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurol.6(2), 188–191 (2007).
  • Fregni F, Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat. Clin. Pract. Neurol.3(7), 383–393 (2007).
  • Boggio PS, Fregni F, Rigonatti SP, Marcolin MA, Silva MT. [Transcranial magnetic stimulation in neuropsychology: new horizons for brain research]. Rev. Bras. Psiquiatr.28(1), 44–49 (2006).
  • Nitsche M, Cohen L, Wasserman EM et al. Transcranial direct current stimulation: state of the art 2008. Brain Stimulation1(3), 206–223 (2008).
  • Zaghi S, Acar M, Hultrgren B, Boggio PS, Fregni F. Noninvasive brain stimulation with low-intensity electrical currents: putative mechanisms of action for direct and alternating current stimulation. Neuroscientist DOI: 10.1177/1073858409336227 (2009) (In Press).
  • Siedentopf CM, Ischebeck A, Haala IA et al. Neural correlates of transmeatal cochlear laser (TCL) stimulation in healthy human subjects. Neurosci. Lett.411(3), 189–193 (2007).
  • Gungor A, Dogru S, Cincik H, Erkul E, Poyrazoglu E. Effectiveness of transmeatal low power laser irradiation for chronic tinnitus. J. Laryngol. Otol.122(5), 447–451 (2008).
  • Tauber S, Schorn K, Beyer W, Baumgartner R. Transmeatal cochlear laser (TCL) treatment of cochlear dysfunction: a feasibility study for chronic tinnitus. Lasers Med. Sci.18(3), 154–161 (2003).
  • Teggi R, Bellini C, Piccioni LO, Palonta F, Bussi M. Transmeatal low-level laser therapy for chronic tinnitus with cochlear dysfunction. Audiol. Neurootol.14(2), 115–120 (2009).
  • Bogdanov OV, Pinchuk D, Pisar’kova EV, Shelyakin AM, Sirbiladze KT. The use of the method of transcranial micropolarization to decrease the severity hyperkineses in patients with infantile cerebral palsy. Neurosci. Behav. Physiol.24(5), 442–445 (1994).
  • Shelyakin AM, Preobrazhenskaya IG, Pisar’kova EV, Pakhomova Zh M, Bogdanov OV. Effects of transcranial micropolarization of the frontal cortex on the state of motor and cognitive functions in extrapyramidal pathology. Neurosci. Behav. Physiol.28(4), 468–471 (1998).
  • Shelyakin AM, Preobrazhenskaya IG, Kassil MV, Bogdanov OV. The effects of transcranial micropolarization on the severity of convulsive fits in children. Neurosci. Behav. Physiol.31(5), 555–560 (2001).
  • Ilyukhina VA, Kozhushko NY, Matveev YK, Ponomareva EA, Chernysheva EM, Shaptilei MA. Transcranial micropolarization in the combined therapy of speech and general psychomotor retardation in children of late preschool age. Neurosci. Behav. Physiol.35(9), 969–976 (2005).
  • Sheliakin AM, Preobrazhenskaia IG, Tiul’kin ON. [Micropolarization of the brain: a noninvasive method for correction of morphological and functional disturbances in acute focal brain lesions and their consequences]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova106(10), 27–37 (2006).
  • Brandt SA, Davis TL, Obrig H et al. Functional magnetic resonance imaging shows localized brain activation during serial transcranial stimulation in man. Neuroreport7(3), 734–736 (1996).
  • Gabis L, Shklar B, Baruch YK, Raz R, Gabis E, Geva D. Pain reduction using transcranial electrostimulation: a double blind “active placebo” controlled trial. J. Rehabil. Med.41(4), 256–261 (2009).
  • Philip P, Demotes-Mainard J, Bourgeois M, Vincent JD. Efficiency of transcranial electrostimulation on anxiety and insomnia symptoms during a washout period in depressed patients. A double-blind study. Biol. Psychiatry29(5), 451–456 (1991).
  • Hozumi S, Hori H, Okawa M, Hishikawa Y, Sato K. Favorable effect of transcranial electrostimulation on behavior disorders in elderly patients with dementia: a double-blind study. Int. J. Neurosci.88(1–2), 1–10 (1996).
  • Evtiukhin AI, Dunaevskii IV, Shabut AM, Aleksandrov VA. [The use of transcranial electrostimulation for pain relief in cancer patients]. Vopr. Onkol.44(2), 229–233 (1998).
  • Lebedev VP, Malygin AV, Kovalevski AV et al. Devices for noninvasive transcranial electrostimulation of the brain endorphinergic system: application for improvement of human psycho-physiological status. Artif. Organs26(3), 248–251 (2002).
  • Gabis L, Shklar B, Geva D. Immediate influence of transcranial electrostimulation on pain and β-endorphin blood levels: an active placebo-controlled study. Am. J. Phys. Med. Rehabil.82(2), 81–85 (2003).
  • Capel ID, Dorrell HM, Spencer EP, Davis MW. The amelioration of the suffering associated with spinal cord injury with subperception transcranial electrical stimulation. Spinal Cord41(2), 109–117 (2003).
  • Markina LD, Kratinova EA. The effects of transcranial electrostimulation on the adaptive state. Neurosci. Behav. Physiol.34(1), 101–104 (2004).
  • Shutov AA, Panasiuk I. [Efficacy of rehabilitation of patients with chronic primary low back pain at the spa Klyuchi using balneopelotherapy and transcranial electrostimulation]. Vopr. Kurortol. Fizioter. Lech. Fiz. Kult. (2), 16–18 (2007).
  • Tarasova SV, Amelin AV, Skoromets AA. [Fluvoxamine, amitriptyline and transcranial electrostimulation of the brain in the treatment of chronic daily headache]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova108(6), 43–46 (2008).
  • Sharova EV, Mel’nikov AV, Novikova MR et al. Changes in spontaneous brain bioelectrical activity during transcranial electrical and electromagnetic stimulation. Neurosci. Behav. Physiol.37(5), 451–457 (2007).
  • Schmitt R, Capo T, Boyd E. Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons. Alcohol Clin. Exp. Res.10(2), 158–160 (1986).
  • Solomon S, Elkind A, Freitag F et al. Safety and effectiveness of cranial electrotherapy in the treatment of tension headache. Headache29(7), 445–450 (1989).
  • Smith RB, Tiberi A, Marshall J. The use of cranial electrotherapy stimulation in the treatment of closed-head-injured patients. Brain Inj.8(4), 357–361 (1994).
  • Padjen AL, Dongier M, Malec T. Effects of cerebral electrical stimulation on alcoholism: a pilot study. Alcohol Clin. Exp. Res.19(4), 1004–1010 (1995).
  • Liss S, Liss B. Physiological and therapeutic effects of high frequency electrical pulses. Integr. Physiol. Behav. Sci.31(2), 88–95 (1996).
  • Pickworth WB, Fant RV, Butschky MF, Goffman AL, Henningfield JE. Evaluation of cranial electrostimulation therapy on short-term smoking cessation. Biol. Psychiatry42(2), 116–121 (1997).
  • Winick RL. Cranial electrotherapy stimulation (CES): a safe and effective low cost means of anxiety control in a dental practice. Gen. Dent.47(1), 50–55 (1999).
  • Southworth S. A study of the effects of cranial electrical stimulation on attention and concentration. Integr. Physiol. Behav. Sci.34(1), 43–53 (1999).
  • Schroeder MJ, Barr RE. Quantitative analysis of the electroencephalogram during cranial electrotherapy stimulation. Clin. Neurophysiol.112(11), 2075–2083 (2001).
  • Scherder EJ, Deijen JB, Vreeswijk SH, Sergeant JA, Swaab DF. Cranial electrostimulation (CES) in patients with probable Alzheimer’s disease. Behav. Brain Res.128(2), 215–217 (2002).
  • Scherder E, Knol D, van Someren E et al. Effects of low-frequency cranial electrostimulation on the rest-activity rhythm and salivary cortisol in Alzheimer’s disease. Neurorehabil. Neural Repair17(2), 101–108 (2003).
  • Scherder EJ, van Tol MJ, Swaab DF. High-frequency cranial electrostimulation (CES) in patients with probable Alzheimer’s disease. Am. J. Phys. Med. Rehabil.85(7), 614–618 (2006).
  • Scherder E, Knol D, van Tol MJ et al. Effects of high-frequency cranial electrostimulation on the rest-activity rhythm and salivary cortisol in Alzheimer’s disease: a pilot study. Dement. Geriatr. Cogn. Disord.22(4), 267–272 (2006).
  • Tan G, Rintala DH, Thornby JI, Yang J, Wade W, Vasilev C. Using cranial electrotherapy stimulation to treat pain associated with spinal cord injury. J. Rehabil. Res. Dev.43(4), 461–474 (2006).
  • Rose KM, Taylor AG, Bourguignon C. Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer’s disease. Appl. Nurs. Res.22(2), 119–125 (2009).
  • Lichtbroun AS, Raicer MM, Smith RB. The treatment of fibromyalgia with cranial electrotherapy stimulation. J. Clin. Rheumatol.7(2), 72–78; discussion 78 (2001).
  • Bell GB, Marino AA, Chesson AL, Struve FA. Human sensitivity to weak magnetic fields. Lancet338(8781), 1521–1522 (1991).
  • Persinger MA, Richards PM, Koren SA. Differential ratings of pleasantness following right and left hemispheric application of low energy magnetic fields that stimulate long-term potentiation. Int. J. Neurosci.79(3–4), 191–197 (1994).
  • Freeman J, Persinger MA. Repeated verbal interruptions during exposure to complex transcerebral magnetic fields elicit irritability: implications for opiate effects. Percept. Mot. Skills82(2), 639–642 (1996).
  • Sandyk R. Effect of weak electromagnetic fields on the amplitude of the pattern reversal VEP response in Parkinson’s disease. Int. J. Neurosci.84(1–4), 165–175 (1996).
  • Lappin MS, Lawrie FW, Richards TL, Kramer ED. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. Altern. Ther. Health Med.9(4), 38–48 (2003).
  • Sieron A, Hese RT, Sobis J, Cieslar G. [Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression]. Psychiatr. Pol.38(2), 217–225 (2004).
  • Cook CM, Thomas AW, Keenliside L, Prato FS. Resting EEG effects during exposure to a pulsed ELF magnetic field. Bioelectromagnetics26(5), 367–376 (2005).
  • Terney D, Chaieb L, Moliadze V, Antal A, Paulus W. Increasing human brain excitability by transcranial high-frequency random noise stimulation. J. Neurosci.28(52), 14147–14155 (2008).
  • ter Haar G. Therapeutic applications of ultrasound. Prog. Biophys. Mol. Biol.93(1–3), 111–129 (2007).
  • Tyler WJ, Tufail Y, Finsterwald M, Tauchmann ML, Olson EJ, Majestic C. Remote excitation of neuronal circuits using low-intensity, low-frequency ultrasound. PLoS One3(10), E3511 (2008).
  • Fry FJ, Ades HW, Fry WJ. Production of reversible changes in the central nervous system by ultrasound. Science127(3289), 83–84 (1958).
  • Gavrilov LR, Gersuni GV, Ilyinsky OB, Sirotyuk MG, Tsirulnikov EM, Shchekanov EE. The effect of focused ultrasound on the skin and deep nerve structures of man and animal. Prog. Brain Res.43, 279–292 (1976).
  • Clement GT, Sun J, Giesecke T, Hynynen K. A hemisphere array for non-invasive ultrasound brain therapy and surgery. Phys. Med. Biol.45(12), 3707–3719 (2000).
  • Hynynen K, Jolesz FA. Demonstration of potential noninvasive ultrasound brain therapy through an intact skull. Ultrasound Med. Biol.24(2), 275–283 (1998).
  • White PJ, Clement GT, Hynynen K. Local frequency dependence in transcranial ultrasound transmission. Phys. Med. Biol.51(9), 2293–2305 (2006).
  • Yin X, Hynynen K. A numerical study of transcranial focused ultrasound beam propagation at low frequency. Phys. Med. Biol.50(8), 1821–1836 (2005).
  • Hynynen K, Clement G. Clinical applications of focused ultrasound-the brain. Int. J. Hyperthermia23(2), 193–202 (2007).
  • Meairs S, Alonso A. Ultrasound, microbubbles and the blood–brain barrier. Prog. Biophys. Mol. Biol.93(1–3), 354–362 (2007).
  • Alamy S, Wei Z, Varia I, Davidson JR, Connor KM. Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J. Psychopharmacol.22(2), 157–161 (2008).
  • Anders M, Tuma I, Rosslerova H. A surveillance study of escitalopram treatment of depressed patients. Expert Opin. Pharmacother.9(1), 1–6 (2008).
  • Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am. J. Geriatr. Psychiatry16(1), 14–20 (2008).
  • Chokka P, Legault M. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial. Depress. Anxiety25(12), E173–E181 (2008).
  • Dell’Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. J. Clin. Psychiatry69(3), 452–456 (2008).
  • Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int. Clin. Psychopharmacol.23(5), 276–286 (2008).
  • Eriksson E, Ekman A, Sinclair S et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J. Clin. Psychopharmacol.28(2), 195–202 (2008).
  • Francois C, Montgomery SA, Despiegel N, Aballea S, Roiz J, Auquier P. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int. J. Clin. Pract.62(11), 1693–1702 (2008).
  • Guerdjikova AI, McElroy SL, Kotwal R et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum. Psychopharmacol.23(1), 1–11 (2008).
  • Hensley PL, Slonimski CK, Uhlenhuth EH, Clayton PJ. Escitalopram: an open-label study of bereavement-related depression and grief. J. Affect. Disord.113(1–2), 142–149 (2009).
  • Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J. Child Adolesc. Psychopharmacol.17(6), 751–760 (2007).
  • Kasper S, Baldwin DS, Larsson Lonn S, Boulenger JP. Superiority of escitalopram to paroxetine in the treatment of depression. Eur. Neuropsychopharmacol.19(4), 229–237 (2009).
  • Kellner M, Demiralay C, Muhtz C et al. No effect of six weeks of treatment with escitalopram on mood in healthy volunteers – irrespective of genotype for the promoter of the serotonin transporter. Psychiatry Res.161(3), 339–343 (2008).
  • Kellner M, Muhtz C, Demiralay C et al. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. J. Psychiatr. Res.43(6), 642–648 (2009).
  • Khan MN, Hotiana UA, Ahmad S. Escitalopram in the treatment of obsessive–compulsive disorder: a double blind placebo control trial. J. Ayub. Med. Coll. Abbottabad.19(4), 58–63 (2007).
  • Lenze EJ, Rollman BL, Shear MK et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA301(3), 295–303 (2009).
  • Leuchter AF, Lesser IM, Trivedi MH et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J. Psychiatr. Pract.14(5), 271–280 (2008).
  • Matrisciano F, Bonaccorso S, Ricciardi A et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J. Psychiatr. Res.43(3), 247–254 (2009).
  • Muhonen LH, Lahti J, Sinclair D, Lonnqvist J, Alho H. Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication. Subst. Abuse Treat. Prev. Policy3, 20 (2008).
  • Muhonen LH, Lonnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J. Clin. Psychiatry69(3), 392–399 (2008).
  • Muller JE, Wentzel I, Koen L, Niehaus DJ, Seedat S, Stein DJ. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol.23(1), 43–48 (2008).
  • Otto M, Bach FW, Jensen TS, Brosen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain139(2), 275–283 (2008).
  • Pinto C, Trivedi JK, Vankar GK, Sharma PS, Narasimha V. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. J. Indian Med. Assoc.105(7), 364, 366, 368 passim (2007).
  • Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive–compulsive disorder. Int. Clin. Psychopharmacol.23(1), 49–53 (2008).
  • Robinson RG, Jorge RE, Moser DJ et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA299(20), 2391–2400 (2008).
  • Stein DJ, Carey PD, Lochner C, Seedat S, Fineberg N, Andersen EW. Escitalopram in obsessive–compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr.13(6), 492–498 (2008).
  • Stella L, Addolorato G, Rinaldi B et al. An open randomized study of the treatment of escitalopram alone and combined with γ-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol. Res.57(4), 312–317 (2008).
  • Uher R, Maier W, Hauser J et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br. J. Psychiatry194(3), 252–259 (2009).
  • Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin. Ther.29(11), 2319–2332 (2007).
  • Allgulander C, Jorgensen T, Wade A et al. Health-related quality of life (HRQOL) among patients with generalised anxiety disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr. Med. Res. Opin.23(10), 2543–2549 (2007).
  • Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl.)196(4), 661–672 (2008).
  • Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry40(4), 152–156 (2007).
  • Black DW, Shaw M, Forbush KT, Allen J. An open-label trial of escitalopram in the treatment of pathological gambling. Clin. Neuropharmacol.30(4), 206–212 (2007).
  • Bose A, Korotzer A, Gommoll C, Li D. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress. Anxiety25(10), 854–861 (2008).
  • Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J. Sex. Med.4(4 Pt 1), 917–929 (2007).
  • Galvao-de Almeida A, Quarantini LC, Gois CR et al. Obsessive–compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr.12(7), 519–524 (2007).
  • Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am. J. Geriatr. Psychiatry15(7), 581–593 (2007).
  • Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty DD. Open-label escitalopram treatment for pathological skin picking. Int. Clin. Psychopharmacol.22(5), 268–274 (2007).
  • Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Investig.27(7), 481–492 (2007).
  • Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr. Med. Res. Opin.23(6), 1303–1318 (2007).
  • Safarinejad MR. Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J. Clin. Psychopharmacol.27(5), 444–450 (2007).
  • Savaskan E, Muller SE, Bohringer A, Schulz A, Schachinger H. Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. Int. J. Neuropsychopharmacol.11(3), 381–388 (2008).
  • Simon NM, Thompson EH, Pollack MH, Shear MK. Complicated grief: a case series using escitalopram. Am. J. Psychiatry164(11), 1760–1761 (2007).
  • Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive–compulsive disorder. Eur. Neuropsychopharmacol.17(6–7), 430–439 (2007).
  • Gadde KM, Ryan Wagner H 2nd, Connor KM, Foust MS. Escitalopram treatment of trichotillomania. Int. Clin. Psychopharmacol.22(1), 39–42 (2007).
  • Kasper S, Lemming OM, de Swart H. Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology54(3), 152–159 (2006).
  • Klein N, Sacher J, Geiss-Granadia T et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared with citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl.)191(2), 333–339 (2007).
  • Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J. Clin. Psychiatry68(3), 422–427 (2007).
  • Koran LM, Aboujaoude EN, Solvason B, Gamel NN, Smith EH. Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J. Clin. Psychopharmacol.27(2), 225–227 (2007).
  • Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J. Clin. Psychiatry67(11), 1767–1775 (2006).
  • Leinonen E, Niemi H. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study. Nord. J. Psychiatry61(2), 109–114 (2007).
  • Mao PX, Tang YL, Jiang F et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress. Anxiety25(1), 46–54 (2008).
  • Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am. J. Geriatr. Pharmacother.4(3), 201–209 (2006).
  • Moller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry40(2), 53–57 (2007).
  • Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin.23(2), 401–416 (2007).
  • Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry40(1), 20–24 (2007).
  • Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of post-traumatic stress disorder. J. Clin. Psychiatry67(10), 1522–1526 (2006).
  • Saghafi R, Brown C, Butters MA et al. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. Int. J. Geriatr. Psychiatry22(11), 1141–1146 (2007).
  • Schmitt L, Tonnoir B, Arbus C. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder. Neuropsychobiology54(4), 201–207 (2006).
  • Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose 24-week study. Curr. Med. Res. Opin.23(4), 701–711 (2007).
  • Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr. Med. Res. Opin.23(2), 245–250 (2007).
  • Winkler D, Pjrek E, Moser U, Kasper S. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum. Psychopharmacol.22(4), 245–251 (2007).
  • Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int. Clin. Psychopharmacol.21(3), 159–169 (2006).
  • Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry189, 264–272 (2006).
  • Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin.22(7), 1331–1341 (2006).
  • Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry67(5), 736–746 (2006).
  • Fonseca M, Soares JC, Hatch JP, Santin AP, Kapczinski F. An open trial of adjunctive escitalopram in bipolar depression. J. Clin. Psychiatry67(1), 81–86 (2006).
  • Freeman MP, Hill R, Brumbach BH. Escitalopram for perimenopausal depression: an open-label pilot study. J. Womens Health (Larchmt)15(7), 857–861 (2006).
  • Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int. Clin. Psychopharmacol.21(4), 203–209 (2006).
  • Klein N, Sacher J, Geiss-Granadia T et al.In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl.)188(3), 263–272 (2006).
  • Olie JP, Tonnoir B, Menard F, Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress. Anxiety24(5), 318–324 (2007).
  • Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int. Clin. Psychopharmacol.21(3), 177–179 (2006).
  • Rao V, Spiro JR, Rosenberg PB, Lee HB, Rosenblatt A, Lyketsos CG. An open-label study of escitalopram (Lexapro) for the treatment of ‘Depression of Alzheimer’s disease’ (dAD). Int. J. Geriatr. Psychiatry21(3), 273–274 (2006).
  • Schmitt L, Arbus C, Tonnoir B. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder – the navigade switch study]. Encephale32(2 Pt 1), 270–277 (2006).
  • Soares CN, Arsenio H, Joffe H et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause13(5), 780–786 (2006).
  • Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann. Clin. Psychiatry18(2), 83–89 (2006).
  • Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J. Am. Acad. Child Adolesc. Psychiatry45(3), 280–288 (2006).
  • Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study. J. Neuropsychiatry Clin. Neurosci.18(3), 377–383 (2006).
  • Wroolie TE, Williams KE, Keller J et al. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J. Clin. Psychopharmacol.26(4), 361–366 (2006).
  • Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol.9(5), 495–505 (2006).
  • Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry17(2), 65–69 (2005).
  • Colonna L, Andersen HF, Reines EH. A randomized, double-blind 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr. Med. Res. Opin.21(10), 1659–1668 (2005).
  • Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry66(11), 1441–1446 (2005).
  • Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J. Clin. Psychiatry66(6), 769–773 (2005).
  • Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am. J. Geriatr. Psychiatry13(10), 884–891 (2005).
  • Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry66(10), 1270–1278 (2005).
  • Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol.20(3), 131–137 (2005).
  • Owley T, Walton L, Salt J et al. An open-label trial of escitalopram in pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry44(4), 343–348 (2005).
  • Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J. Clin. Psychopharmacol.26(1), 67–70 (2006).
  • Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress. Anxiety21(1), 26–32 (2005).
  • Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J. Clin. Psychiatry65(9), 1190–1196 (2004).
  • Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry63(4), 331–336 (2002).
  • Camarasa X, Lopez-Martinez E, Duboc A, Khazaal Y, Zullino DF. Escitalopram/reboxetine combination in depressed patients with substance use disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry29(1), 165–168 (2005).
  • Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19(4), 234–240 (2004).
  • Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry186, 222–226 (2005).
  • Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety19(4), 241–248 (2004).
  • Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.18(4), 211–217 (2003).
  • Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology50(1), 57–64 (2004).
  • Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin. Psychiatry65(1), 44–49 (2004).
  • Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J. Clin. Psychopharmacol.24(2), 209–213 (2004).
  • Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry64(11), 1322–1327 (2003).
  • Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.17(3), 95–102 (2002).
  • Hubble JP, Koller WC, Cutler NR et al. Pramipexole in patients with early Parkinson’s disease. Clin. Neuropharmacol.18(4), 338–347 (1995).
  • Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum.52(8), 2495–2505 (2005).
  • Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61(7), 1044–1053 (2004).
  • Hamidovic A, Kang UJ, de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J. Clin. Psychopharmacol.28(1), 45–51 (2008).
  • Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology56(11), 1559–1564 (2001).
  • Guttman M; International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology49(4), 1060–1065 (1997).
  • Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry161(3), 564–566 (2004).
  • Ferini-Strambi L, Aarskog D, Partinen M et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med.9(8), 874–881 (2008).
  • Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology61(10), 1418–1420 (2003).
  • Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Meco G. Pramipexole in Parkinson’s disease. A short-term study using the combined levodopa-dopamine agonist test. Funct. Neurol.17(4), 199–201 (2002).
  • Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia47(5), 1374–1381 (2009).
  • Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety11(2), 58–65 (2000).
  • Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K; CALM-PD Investigators of the Parkinson Study Group. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov. Disord.22(9), 1317–1319 (2007).
  • Ciraulo DA, Sarid-Segal O, Knapp CM et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction100(Suppl. 1), 12–22 (2005).
  • Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress. Anxiety20(3), 131–138 (2004).
  • Brusa L, Bassi A, Stefani A et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J. Neural Transm.110(4), 373–380 (2003).
  • Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology51(4), 1221–1223 (1998).
  • Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol.253(5), 601–607 (2006).
  • Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin. Neuropharmacol.23(1), 34–44 (2000).
  • Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA278(2), 125–130 (1997).
  • Zarate CA Jr, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry56(1), 54–60 (2004).
  • Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J. Neurol. Sci.216(1), 81–87 (2003).
  • Winkelman JW, Sethi KD, Kushida CA et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology67(6), 1034–1039 (2006).
  • Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology52(4), 873–874 (1999).
  • Vida Z, Szakacs Z. [Pramipexole therapy of restless legs syndrome]. Ideggyogy Sz.60(1–2), 15–22 (2007).
  • Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov. Disord.21(9), 1404–1410 (2006).
  • Streeter CC, Hennen J, Ke Y et al. Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment. Psychopharmacology (Berl.)182(4), 516–526 (2005).
  • Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology50(1), 65–70 (2004).
  • Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep26(7), 819–821 (2003).
  • Shannon KM, Bennett JP Jr, Friedman JH; The Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology49(3), 724–728 (1997).
  • Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin. Pharmacol. Ther.51(5), 541–548 (1992).
  • Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J. Psychopharmacol.20(6), 756–770 (2006).
  • Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology (Berl.)187(4), 498–510 (2006).
  • Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur. Arch. Psychiatry Clin. Neurosci.252(4), 185–194 (2002).
  • Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10(4), 399–406 (2003).
  • Reichmann H, Brecht HM, Kraus PH, Lemke MR. [Pramipexole in Parkinson disease. Results of a treatment observation]. Nervenarzt73(8), 745–750 (2002).
  • Provini F, Albani F, Vetrugno R et al. A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder. Eur. J. Neurol.12(6), 432–436 (2005).
  • Pogarell O, Gasser T, van Hilten JJ et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J. Neurol. Neurosurg. Psychiatry72(6), 713–720 (2002).
  • Poewe WH, Rascol O, Quinn N et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol.6(6), 513–520 (2007).
  • Pinter MM, Rutgers AW, Hebenstreit E. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson’s disease. J. Neural Transm.107(11), 1307–1323 (2000).
  • Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J. Neurol. Neurosurg. Psychiatry66(4), 436–441 (1999).
  • Pattee GL, Post GR, Gerber RE, Bennett JP Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph Lateral Scler. Other Motor Neuron Disord.4(2), 90–95 (2003).
  • Partinen M, Hirvonen K, Jama L et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study – the PRELUDE study. Sleep Med.7(5), 407–417 (2006).
  • Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin. Neuropharmacol.30(2), 72–85 (2007).
  • Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287(13), 1653–1661 (2002).
  • Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA284(15), 1931–1938 (2000).
  • Oertel WH, Stiasny-Kolster K, Bergtholdt B et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov. Disord.22(2), 213–219 (2007).
  • Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health9(1), 28–38 (2006).
  • Navan P, Findley LJ, Undy MB, Pearce RK, Bain PG. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur. J. Neurol.12(1), 1–8 (2005).
  • Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s disease. Mov. Disord.18(2), 176–180 (2003).
  • Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov. Disord.18(11), 1324–1331 (2003).
  • Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology52(5), 938–943 (1999).
  • Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur. J. Neurol.7(Suppl. 1), 27–31 (2000).
  • Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov. Disord.20(5), 602–610 (2005).
  • Molho ES, Factor SA, Weiner WJ et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease. J. Neural Transm. Suppl.45, 225–230 (1995).
  • Mizuno Y, Yanagisawa N, Kuno S et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov. Disord.18(10), 1149–1156 (2003).
  • Merlino G, Dolso P, Canesin R, Cancelli I, Valente M, Gigli GL. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology54(3), 195–200 (2006).
  • Manconi M, Ferri R, Zucconi M et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med.8(5), 491–497 (2007).
  • Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology49(1), 162–168 (1997).
  • Letvinenko IV, Odinak MM, Mogil’naia VI. [Pain and depression in Parkinson’s disease: new therapeutic possibilities of pramipexole]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova108(11), 36–38 (2008).
  • Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J. Neurol. Sci.248(1–2), 266–270 (2006).
  • Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci.17(2), 214–220 (2005).
  • Lattanzi L, Dell’Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord.4(5), 307–314 (2002).
  • Kunig G, Pogarell O, Moller JC, Delf M, Oertel WH. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin. Neuropharmacol.22(5), 301–305 (1999).
  • Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E. Increase in body weight after pramipexole treatment in Parkinson’s disease. Mov. Disord.21(11), 1972–1974 (2006).
  • Kasper S, Barnas C, Heiden A et al. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur. Neuropsychopharmacol.7(1), 65–70 (1997).
  • Boggio PS, Bermpohl F, Vergara AO et al. Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression. J. Affect. Disord.101(1–3), 91–98 (2007).
  • Boggio PS, Rigonatti SP, Ribeiro RB et al. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int. J. Neuropsychopharmacol.11(2), 249–254 (2008).
  • Boggio PS, Rocha RR, da Silva MT, Fregni F. Differential modulatory effects of transcranial direct current stimulation on a facial expression go-no-go task in males and females. Neurosci. Lett.447(2–3), 101–105 (2008).
  • Boggio PS, Sultani N, Fecteau S et al. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend.92(1–3), 55–60 (2008).
  • Boggio PS, Zaghi S, Lopes M, Fregni F. Modulatory effects of anodal transcranial direct current stimulation on perception and pain thresholds in healthy volunteers. Eur. J. Neurol.15(10), 1124–1130 (2008).
  • Fecteau S, Pascual-Leone A, Zald DH et al. Activation of prefrontal cortex by transcranial direct current stimulation reduces appetite for risk during ambiguous decision making. J. Neurosci.27(23), 6212–6218 (2007).
  • Floel A, Rosser N, Michka O, Knecht S, Breitenstein C. Noninvasive brain stimulation improves language learning. J. Cogn. Neurosci.20(8), 1415–1422 (2008).
  • Fregni F, Boggio PS, Lima MC et al. A sham-controlled, Phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain122(1–2), 197–209 (2006).
  • Fregni F, Boggio PS, Mansur CG et al. Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport16(14), 1551–1555 (2005).
  • Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord.8(2), 203–204 (2006).
  • Fregni F, Boggio PS, Nitsche MA, Rigonatti SP, Pascual-Leone A. Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depress. Anxiety23(8), 482–484 (2006).
  • Fregni F, Gimenes R, Valle AC et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum.54(12), 3988–3998 (2006).
  • Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. J. Clin. Psychiatry69(1), 32–40 (2008).
  • Fregni F, Marcondes R, Boggio PS et al. Transient tinnitus suppression induced by repetitive transcranial magnetic stimulation and transcranial direct current stimulation. Eur. J. Neurol.13(9), 996–1001 (2006).
  • Fregni F, Orsati F, Pedrosa W et al. Transcranial direct current stimulation of the prefrontal cortex modulates the desire for specific foods. Appetite51(1), 34–41 (2008).
  • Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin. Neurophysiol.117(4), 845–850 (2006).
  • Hesse S, Werner C, Schonhardt EM, Bardeleben A, Jenrich W, Kirker SG. Combined transcranial direct current stimulation and robot-assisted arm training in subacute stroke patients: a pilot study. Restor. Neurol. Neurosci.25(1), 9–15 (2007).
  • Hummel F, Celnik P, Giraux P et al. Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke. Brain128(Pt 3), 490–499 (2005).
  • Jo JM, Kim YH, Ko MH, Ohn SH, Joen B, Lee KH. Enhancing the working memory of stroke patients using tDCS. Am. J. Phys. Med. Rehabil.88(5), 404–409 (2009).
  • Kincses TZ, Antal A, Nitsche MA, Bartfai O, Paulus W. Facilitation of probabilistic classification learning by transcranial direct current stimulation of the prefrontal cortex in the human. Neuropsychologia42(1), 113–117 (2004).
  • Knoch D, Nitsche MA, Fischbacher U, Eisenegger C, Pascual-Leone A, Fehr E. Studying the neurobiology of social interaction with transcranial direct current stimulation – the example of punishing unfairness. Cereb. Cortex18(9), 1987–1990 (2008).
  • Ko MH, Han SH, Park SH, Seo JH, Kim YH. Improvement of visual scanning after DC brain polarization of parietal cortex in stroke patients with spatial neglect. Neurosci. Lett.448(2), 171–174 (2008).
  • Koenigs M, Ukueberuwa D, Campion P, Grafman J, Wassermann E. Bilateral frontal transcranial direct current stimulation: failure to replicate classic findings in healthy subjects. Clin. Neurophysiol.120(1), 80–84 (2009).
  • Marshall L, Molle M, Hallschmid M, Born J. Transcranial direct current stimulation during sleep improves declarative memory. J. Neurosci.24(44), 9985–9992 (2004).
  • Ohn SH, Park CI, Yoo WK et al. Time-dependent effect of transcranial direct current stimulation on the enhancement of working memory. Neuroreport19(1), 43–47 (2008).
  • Rango M, Cogiamanian F, Marceglia S et al. Myoinositol content in the human brain is modified by transcranial direct current stimulation in a matter of minutes: a 1H-MRS study. Magn. Reson. Med.60(4), 782–789 (2008).
  • Roizenblatt S, Fregni F, Gimenez R et al. Site-specific effects of transcranial direct current stimulation on sleep and pain in fibromyalgia: a randomized, sham-controlled study. Pain Pract.7(4), 297–306 (2007).
  • Sparing R, Dafotakis M, Meister IG, Thirugnanasambandam N, Fink GR. Enhancing language performance with non-invasive brain stimulation – a transcranial direct current stimulation study in healthy humans. Neuropsychologia46(1), 261–268 (2008).
  • Terney D, Bergmann I, Poreisz C et al. Pergolide increases the efficacy of cathodal direct current stimulation to reduce the amplitude of laser-evoked potentials in humans. J. Pain Symptom Manage.36(1), 79–91 (2008).
  • Vines BW, Nair DG, Schlaug G. Contralateral and ipsilateral motor effects after transcranial direct current stimulation. Neuroreport17(6), 671–674 (2006).
  • Alonso P, Pujol J, Cardoner N et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive–compulsive disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry158(7), 1143–1145 (2001).
  • Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction104(4), 653–660 (2009).
  • Anderson IM, Delvai NA, Ashim B et al. Adjunctive fast repetitive transcranial magnetic stimulation in depression. Br. J. Psychiatry190, 533–534 (2007).
  • Andre-Obadia N, Peyron R, Mertens P, Mauguiere F, Laurent B, Garcia-Larrea L. Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy. Clin. Neurophysiol.117(7), 1536–1544 (2006).
  • Avery DH, Holtzheimer PE 3rd, Fawaz W et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol. Psychiatry59(2), 187–194 (2006).
  • Avery DH, Holtzheimer PE 3rd, Fawaz W et al. Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled study. J. Nerv. Ment. Dis.195(5), 378–381 (2007).
  • Avery DH, Isenberg KE, Sampson SM et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J. Clin. Psychiatry69(3), 441–451 (2008).
  • Baeken C, Leyman L, De Raedt R, Vanderhasselt MA, D’Haenen H. Lack of impact of repetitive high frequency transcranial magnetic stimulation on mood in healthy female subjects. J. Affect. Disord.90(1), 63–66 (2006).
  • Bagati D, Nizamie SH, Prakash R. Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Aust. N. Z. J. Psychiatry43(4), 386–392 (2009).
  • Benadhira R, Saba G, Samaan A et al. Transcranial magnetic stimulation for refractory depression. Am. J. Psychiatry162(1), 193 (2005).
  • Berman RM, Narasimhan M, Sanacora G et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol. Psychiatry47(4), 332–337 (2000).
  • Borckardt JJ, Smith AR, Reeves ST et al. Fifteen minutes of left prefrontal repetitive transcranial magnetic stimulation acutely increases thermal pain thresholds in healthy adults. Pain Res. Manag.12(4), 287–290 (2007).
  • Borckardt JJ, Weinstein M, Reeves ST et al. Postoperative left prefrontal repetitive transcranial magnetic stimulation reduces patient-controlled analgesia use. Anesthesiology105(3), 557–562 (2006).
  • Bornke C, Schulte T, Przuntek H, Muller T. Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson’s disease. J. Neural Transm. Suppl. (68), 61–67 (2004).
  • Bortolomasi M, Minelli A, Fuggetta G et al. Long-lasting effects of high frequency repetitive transcranial magnetic stimulation in major depressed patients. Psychiatry Res.150(2), 181–186 (2007).
  • Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Res.113(3), 245–254 (2002).
  • Boylan LS, Pullman SL, Lisanby SH, Spicknall KE, Sackeim HA. Repetitive transcranial magnetic stimulation to SMA worsens complex movements in Parkinson’s disease. Clin. Neurophysiol.112(2), 259–264 (2001).
  • Bretlau LG, Lunde M, Lindberg L, Unden M, Dissing S, Bech P. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry41(2), 41–47 (2008).
  • Brusa L, Versace V, Koch G et al. Improvement of choreic movements by 1 Hz repetitive transcranial magnetic stimulation in Huntington’s disease patients. Ann Neurol.58(4), 655–656 (2005).
  • Camprodon JA, Martinez-Raga J, Alonso-Alonso M, Shih MC, Pascual-Leone A. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. Drug Alcohol Depend.86(1), 91–94 (2007).
  • Catafau AM, Perez V, Gironell A et al. SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Res.106(3), 151–160 (2001).
  • Centonze D, Koch G, Versace V et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology68(13), 1045–1050 (2007).
  • Chae JH, Nahas Z, Wassermann E et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette’s syndrome. Cogn. Behav. Neurol.17(2), 109–117 (2004).
  • Chibbaro G, Daniele M, Alagona G et al. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations. Neurosci. Lett.383(1–2), 54–57 (2005).
  • Chistyakov AV, Kaplan B, Rubichek O et al. Antidepressant effects of different schedules of repetitive transcranial magnetic stimulation vs. clomipramine in patients with major depression: relationship to changes in cortical excitability. Int. J. Neuropsychopharmacol.8(2), 223–233 (2005).
  • Chistyakov AV, Kaplan B, Rubichek O et al. Effect of electroconvulsive therapy on cortical excitability in patients with major depression: a transcranial magnetic stimulation study. Clin. Neurophysiol.116(2), 386–392 (2005).
  • Clarke BM, Upton AR, Kamath MV, Al-Harbi T, Castellanos CM. Transcranial magnetic stimulation for migraine: clinical effects. J. Headache Pain7(5), 341–346 (2006).
  • Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in post-traumatic stress disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry161(3), 515–524 (2004).
  • Conca A, Koppi S, Konig P, Swoboda E, Krecke N. Transcranial magnetic stimulation: a novel antidepressive strategy? Neuropsychobiology34(4), 204–207 (1996).
  • Cotelli M, Manenti R, Cappa SF, Zanetti O, Miniussi C. Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. Eur. J. Neurol.15(12), 1286–1292 (2008).
  • Crevits L, Van den Abbeele D, Audenaert K, Goethals M, Dierick M. Effect of repetitive transcranial magnetic stimulation on saccades in depression: a pilot study. Psychiatry Res.135(2), 113–119 (2005).
  • d’Alfonso AA, Aleman A, Kessels RP et al. Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: effects on hallucinations and neurocognition. J. Neuropsychiatry Clin. Neurosci.14(1), 77–79 (2002).
  • del Olmo MF, Bello O, Cudeiro J. Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson’s disease. Clin. Neurophysiol.118(1), 131–139 (2007).
  • Dell’Osso B, Mundo E, D’Urso N et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord.11(1), 76–81 (2009).
  • Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J. Clin. Psychiatry69(6), 930–934 (2008).
  • Di Lazzaro V, Dileone M, Pilato F et al. Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study. Neurosci. Lett.408(2), 135–140 (2006).
  • Dias AE, Barbosa ER, Coracini K, Maia F, Marcolin MA, Fregni F. Effects of repetitive transcranial magnetic stimulation on voice and speech in Parkinson’s disease. Acta Neurol. Scand.113(2), 92–99 (2006).
  • Dolberg OT, Dannon PN, Schreiber S, Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study. Bipolar Disord.4(Suppl. 1), 94–95 (2002).
  • Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study. Mov. Disord.17(3), 528–532 (2002).
  • Eichhammer P, Johann M, Kharraz A et al. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J. Clin. Psychiatry64(8), 951–953 (2003).
  • Eichhammer P, Kharraz A, Wiegand R et al. Sleep deprivation in depression stabilizing antidepressant effects by repetitive transcranial magnetic stimulation. Life Sci.70(15), 1741–1749 (2002).
  • Eichhammer P, Langguth B, Marienhagen J, Kleinjung T, Hajak G. Neuronavigated repetitive transcranial magnetic stimulation in patients with tinnitus: a short case series. Biol. Psychiatry54(8), 862–865 (2003).
  • Eranti S, Mogg A, Pluck G et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am. J. Psychiatry164(1), 73–81 (2007).
  • Eschweiler GW, Wegerer C, Schlotter W et al. Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Res.99(3), 161–172 (2000).
  • Fabre I, Galinowski A, Oppenheim C et al. Antidepressant efficacy and cognitive effects of repetitive transcranial magnetic stimulation in vascular depression: an open trial. Int. J. Geriatr. Psychiatry19(9), 833–842 (2004).
  • Figiel GS, Epstein C, McDonald WM et al. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. J. Neuropsychiatry Clin. Neurosci.10(1), 20–25 (1998).
  • Filipovic SR, Rothwell JC, van de Warrenburg BP, Bhatia K. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson’s disease. Mov. Disord.24(2), 246–253 (2009).
  • Fitzgerald PB, Benitez J, Daskalakis JZ et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J. Clin. Psychopharmacol.25(4), 358–362 (2005).
  • Fitzgerald PB, Benitez J, de Castella A, Daskalakis ZJ, Brown TL, Kulkarni J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am. J. Psychiatry163(1), 88–94 (2006).
  • Fitzgerald PB, Benitez J, de Castella AR, Brown TL, Daskalakis ZJ, Kulkarni J. Naturalistic study of the use of transcranial magnetic stimulation in the treatment of depressive relapse. Aust. NZ J. Psychiatry40(9), 764–768 (2006).
  • Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry60(10), 1002–1008 (2003).
  • Fitzgerald PB, Fountain S, Hoy K et al. A comparative study of the effects of repetitive paired transcranial magnetic stimulation on motor cortical excitability. J. Neurosci. Methods165(2), 265–269 (2007).
  • Fitzgerald PB, Hoy K, Daskalakis ZJ, Kulkarni J. A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression. Depress. Anxiety26(3), 229–234 (2009).
  • Fitzgerald PB, Hoy K, McQueen S et al. Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. J. Clin. Psychopharmacol.28(1), 52–58 (2008).
  • Fitzgerald PB, Huntsman S, Gunewardene R, Kulkarni J, Daskalakis ZJ. A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. Int. J. Neuropsychopharmacol.9(6), 655–666 (2006).
  • Fitzgerald PB, Sritharan A, Daskalakis ZJ, de Castella AR, Kulkarni J, Egan G. A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression. J. Clin. Psychopharmacol.27(5), 488–492 (2007).
  • Folmer RL, Carroll JR, Rahim A, Shi Y, Hal Martin W. Effects of repetitive transcranial magnetic stimulation (rTMS) on chronic tinnitus. Acta Otolaryngol. Suppl. (556), 96–101 (2006).
  • Marcondes R, Fregni F, Pascual-Leone A. Tinnitus and brain activation: insights from transcranial magnetic stimulation. Ear Nose Throat J.85(4), 233–234, 236–238 (2006).
  • Fregni F, Santos CM, Myczkowski ML et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry75(8), 1171–1174 (2004).
  • Fujita K, Koga Y. Clinical application of single-pulse transcranial magnetic stimulation for the treatment of depression. Psychiatry Clin. Neurosci.59(4), 425–432 (2005).
  • Funk AP, George MS. Prefrontal EEG asymmetry as a potential biomarker of antidepressant treatment response with transcranial magnetic stimulation (TMS): a case series. Clin. EEG Neurosci.39(3), 125–130 (2008).
  • Garcia-Toro M, Mayol A, Arnillas H et al. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression. J. Affect. Disord.64(2–3), 271–275 (2001).
  • Garcia-Toro M, Pascual-Leone A, Romera M et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. J. Neurol. Neurosurg. Psychiatry71(4), 546–548 (2001).
  • Garcia-Toro M, Salva J, Daumal J et al. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. Psychiatry Res.146(1), 53–57 (2006).
  • George MS, Wassermann EM, Kimbrell TA et al. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am. J. Psychiatry154(12), 1752–1756 (1997).
  • Gironell A, Kulisevsky J, Lorenzo J, Barbanoj M, Pascual-Sedano B, Otermin P. Transcranial magnetic stimulation of the cerebellum in essential tremor: a controlled study. Arch. Neurol.59(3), 413–417 (2002).
  • Goto T, Saitoh Y, Hashimoto N et al. Diffusion tensor fiber tracking in patients with central post-stroke pain; correlation with efficacy of repetitive transcranial magnetic stimulation. Pain140(3), 509–518 (2008).
  • Goyal N, Nizamie SH, Desarkar P. Efficacy of adjuvant high frequency repetitive transcranial magnetic stimulation on negative and positive symptoms of schizophrenia: preliminary results of a double-blind sham-controlled study. J. Neuropsychiatry Clin. Neurosci.19(4), 464–467 (2007).
  • Graff-Guerrero A, Gonzalez-Olvera J, Fresan A, Gomez-Martin D, Mendez-Nunez JC, Pellicer F. Repetitive transcranial magnetic stimulation of dorsolateral prefrontal cortex increases tolerance to human experimental pain. Brain Res. Cogn. Brain Res.25(1), 153–160 (2005).
  • Greenberg BD, George MS, Martin JD et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive–compulsive disorder: a preliminary study. Am. J. Psychiatry154(6), 867–869 (1997).
  • Grisaru N, Amir M, Cohen H, Kaplan Z. Effect of transcranial magnetic stimulation in post-traumatic stress disorder: a preliminary study. Biol. Psychiatry44(1), 52–55 (1998).
  • Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH. Transcranial magnetic stimulation in mania: a controlled study. Am. J. Psychiatry155(11), 1608–1610 (1998).
  • Grunhaus L, Dannon PN, Schreiber S et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol. Psychiatry47(4), 314–324 (2000).
  • Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol. Psychiatry53(4), 324–331 (2003).
  • Habel U, Wild B, Topka H, Kircher T, Salloum JB, Schneider F. Transcranial magnetic stimulation: no effect on mood with single pulse during learned helplessness. Prog. Neuropsychopharmacol. Biol. Psychiatry25(3), 497–506 (2001).
  • Hajak G, Marienhagen J, Langguth B, Werner S, Binder H, Eichhammer P. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol. Med.34(7), 1157–1163 (2004).
  • Hausmann A, Kemmler G, Walpoth M et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled “add on” trial. J. Neurol. Neurosurg. Psychiatry75(2), 320–322 (2004).
  • Herwig U, Fallgatter AJ, Hoppner J et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br. J. Psychiatry191, 441–448 (2007).
  • Hirayama A, Saitoh Y, Kishima H et al. Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortex. Pain122(1–2), 22–27 (2006).
  • Hoffman RE, Boutros NN, Berman RM et al. Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated “voices”. Biol. Psychiatry46(1), 130–132 (1999).
  • Hoffman RE, Boutros NN, Hu S, Berman RM, Krystal JH, Charney DS. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet355(9209), 1073–1075 (2000).
  • Hoffman RE, Gueorguieva R, Hawkins KA et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol. Psychiatry58(2), 97–104 (2005).
  • Hoffman RE, Hawkins KA, Gueorguieva R et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch. Gen. Psychiatry60(1), 49–56 (2003).
  • Holi MM, Eronen M, Toivonen K, Toivonen P, Marttunen M, Naukkarinen H. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophr. Bull.30(2), 429–434 (2004).
  • Holtzheimer PE 3rd, Russo J, Claypoole KH, Roy-Byrne P, Avery DH. Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation. Depress. Anxiety19(1), 24–30 (2004).
  • Huang CC, Su TP, Shan IK, Wei IH. Effect of 5 Hz repetitive transcranial magnetic stimulation on cognition during a Go/NoGo task. J. Psychiatr. Res.38(5), 513–520 (2004).
  • Huber TJ, Schneider U, Rollnik J. Gender differences in the effect of repetitive transcranial magnetic stimulation in schizophrenia. Psychiatry Res.120(1), 103–105 (2003).
  • Ihara Y, Takata H, Tanabe Y, Nobukuni K, Hayabara T. Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. Neurol. Res.27(3), 310–313 (2005).
  • Ikeguchi M, Touge T, Nishiyama Y, Takeuchi H, Kuriyama S, Ohkawa M. Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson’s disease. J. Neurol. Sci.209(1–2), 41–46 (2003).
  • Irlbacher K, Kuhnert J, Roricht S, Meyer BU, Brandt SA. [Central and peripheral deafferent pain: therapy with repetitive transcranial magnetic stimulation]. Nervenarzt77(10), 1196, 1198–1203 (2006).
  • Izumi S, Kondo T, Shindo K. Transcranial magnetic stimulation synchronized with maximal movement effort of the hemiplegic hand after stroke: a double-blinded controlled pilot study. J. Rehabil. Med.40(1), 49–54 (2008).
  • Jakob F, Brakemeier EL, Schommer NC et al. Ultrahigh frequency repetitive transcranial magnetic stimulation in unipolar depression. J. Clin. Psychopharmacol.28(4), 474–476 (2008).
  • Jandl M, Bittner R, Sack A et al. Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): an open-label pilot study. J. Neural Transm.112(7), 955–967 (2005).
  • Jandl M, Steyer J, Weber M et al. Treating auditory hallucinations by transcranial magnetic stimulation: a randomized controlled cross-over trial. Neuropsychobiology53(2), 63–69 (2006).
  • Janicak PG, Dowd SM, Martis B et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biol. Psychiatry51(8), 659–667 (2002).
  • Januel D, Dumortier G, Verdon CM et al. A double-blind sham controlled study of right prefrontal repetitive transcranial magnetic stimulation (rTMS): therapeutic and cognitive effect in medication free unipolar depression during 4 weeks. Prog. Neuropsychopharmacol. Biol. Psychiatry30(1), 126–130 (2006).
  • Jin X, Wu X, Wang J et al. [Effect of transcranial magnetic stimulation on rehabilitation of motor function in patients with cerebral infarction]. Zhonghua Yi Xue Za Zhi82(8), 534–537 (2002).
  • Johann M, Wiegand R, Kharraz A et al. [Transcranial magnetic stimulation for nicotine dependence]. Psychiatr. Prax.30(Suppl. 2), S129–S131 (2003).
  • Joo EY, Han SJ, Chung SH, Cho JW, Seo DW, Hong SB. Antiepileptic effects of low-frequency repetitive transcranial magnetic stimulation by different stimulation durations and locations. Clin. Neurophysiol.118(3), 702–708 (2007).
  • Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch. Gen. Psychiatry65(3), 268–276 (2008).
  • Jorge RE, Robinson RG, Tateno A et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol. Psychiatry55(4), 398–405 (2004).
  • Kauffmann CD, Cheema MA, Miller BE. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. Depress. Anxiety19(1), 59–62 (2004).
  • Khedr EM, Abo-Elfetoh N, Rothwell JC. Treatment of post-stroke dysphagia with repetitive transcranial magnetic stimulation. Acta Neurol. Scand.119(3), 155–161 (2009).
  • Khedr EM, Farweez HM, Islam H. Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson’s disease patients. Eur. J. Neurol.10(5), 567–572 (2003).
  • Khedr EM, Rothwell JC, Ahmed MA, El-Atar A. Effect of daily repetitive transcranial magnetic stimulation for treatment of tinnitus: comparison of different stimulus frequencies. J. Neurol. Neurosurg. Psychiatry79(2), 212–215 (2008).
  • Khedr EM, Rothwell JC, Shawky OA, Ahmed MA, Foly N, Hamdy A. Dopamine levels after repetitive transcranial magnetic stimulation of motor cortex in patients with Parkinson’s disease: preliminary results. Mov. Disord.22(7), 1046–1050 (2007).
  • Khedr EM, Rothwell JC, Shawky OA, Ahmed MA, Hamdy A. Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson’s disease. Mov. Disord.21(12), 2201–2205 (2006).
  • Kim JY, Chung EJ, Lee WY et al. Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson’s disease: analysis of [11C] raclopride PET study. Mov. Disord.23(2), 207–211 (2008).
  • Kinoshita M, Ikeda A, Begum T, Yamamoto J, Hitomi T, Shibasaki H. Low-frequency repetitive transcranial magnetic stimulation for seizure suppression in patients with extratemporal lobe epilepsy-a pilot study. Seizure14(6), 387–392 (2005).
  • Kirton A, Chen R, Friefeld S, Gunraj C, Pontigon AM, Deveber G. Contralesional repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. Lancet Neurol.7(6), 507–513 (2008).
  • Kito S, Fujita K, Koga Y. Regional cerebral blood flow changes after low-frequency transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in treatment-resistant depression. Neuropsychobiology58(1), 29–36 (2008).
  • Klein E, Kolsky Y, Puyerovsky M, Koren D, Chistyakov A, Feinsod M. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biol. Psychiatry46(10), 1451–1454 (1999).
  • Klein E, Kreinin I, Chistyakov A et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch. Gen. Psychiatry56(4), 315–320 (1999).
  • Kleinjung T, Eichhammer P, Langguth B et al. Long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic tinnitus. Otolaryngol. Head Neck Surg.132(4), 566–569 (2005).
  • Kleinjung T, Steffens T, Langguth B et al. [Treatment of chronic tinnitus with neuronavigated repetitive transcranial magnetic stimulation (rTMS)]. HNO54(6), 439–444 (2006).
  • Koerselman F, Laman DM, van Duijn H, van Duijn MA, Willems MA. A 3-month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. J. Clin. Psychiatry65(10), 1323–1328 (2004).
  • Langguth B, Eichhammer P, Zowe M et al. [Low frequency repetitive transcranial magnetic stimulation (rTMS) for the treatment of chronic tinnitus – are there long-term effects?]. Psychiatr. Prax.31(Suppl. 1), S52–S54 (2004).
  • Langguth B, Wiegand R, Kharraz A et al. Pre-treatment anterior cingulate activity as a predictor of antidepressant response to repetitive transcranial magnetic stimulation (rTMS). Neuro Endocrinol. Lett.28(5), 633–638 (2007).
  • Lee SL, Abraham M, Cacace AT, Silver SM. Repetitive transcranial magnetic stimulation in veterans with debilitating tinnitus: a pilot study. Otolaryngol. Head Neck Surg.138(3), 398–399 (2008).
  • Lefaucheur JP, Drouot X, Keravel Y, Nguyen JP. Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex. Neuroreport12(13), 2963–2965 (2001).
  • Lefaucheur JP, Drouot X, Menard-Lefaucheur I et al. Neurogenic pain relief by repetitive transcranial magnetic cortical stimulation depends on the origin and the site of pain. J. Neurol. Neurosurg. Psychiatry75(4), 612–616 (2004).
  • Lefaucheur JP, Drouot X, Nguyen JP. Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex. Neurophysiol. Clin.31(4), 247–252 (2001).
  • Lefaucheur JP, Drouot X, Von Raison F, Menard-Lefaucheur I, Cesaro P, Nguyen JP. Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson’s disease. Clin. Neurophysiol.115(11), 2530–2541 (2004).
  • Levkovitz Y, Roth Y, Harel EV, Braw Y, Sheer A, Zangen A. A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation. Clin. Neurophysiol.118(12), 2730–2744 (2007).
  • Liepert J, Zittel S, Weiller C. Improvement of dexterity by single session low-frequency repetitive transcranial magnetic stimulation over the contralesional motor cortex in acute stroke: a double-blind placebo-controlled crossover trial. Restor. Neurol. Neurosci.25(5–6), 461–465 (2007).
  • Lisanby SH, Husain MM, Rosenquist PB et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology34(2), 522–534 (2009).
  • Little JT, Kimbrell TA, Wassermann EM et al. Cognitive effects of 1- and 20-Hertz repetitive transcranial magnetic stimulation in depression: preliminary report. Neuropsychiatry Neuropsychol. Behav. Neurol.13(2), 119–124 (2000).
  • Loo C, McFarquhar T, Walter G. Transcranial magnetic stimulation in adolescent depression. Australas Psychiatry14(1), 81–85 (2006).
  • Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am. J. Psychiatry156(6), 946–948 (1999).
  • Loo CK, Mitchell PB, Croker VM et al. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. Psychol. Med.33(1), 33–40 (2003).
  • Maihofner C, Ropohl A, Reulbach U et al. Effects of repetitive transcranial magnetic stimulation in depression: a magnetoencephalographic study. Neuroreport16(16), 1839–1842 (2005).
  • Malcolm MP, Triggs WJ, Light KE et al. Repetitive transcranial magnetic stimulation as an adjunct to constraint-induced therapy: an exploratory randomized controlled trial. Am. J. Phys. Med. Rehabil.86(9), 707–715 (2007).
  • Mally J, Dinya E. Recovery of motor disability and spasticity in post-stroke after repetitive transcranial magnetic stimulation (rTMS). Brain Res. Bull.76(4), 388–395 (2008).
  • Mally J, Stone TW. Therapeutic and “dose-dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson’s disease. J. Neurosci. Res.57(6), 935–940 (1999).
  • Mally J, Stone TW. Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J. Neurol. Sci.162(2), 179–184 (1999).
  • Manes F, Jorge R, Morcuende M, Yamada T, Paradiso S, Robinson RG. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int. Psychogeriatr.13(2), 225–231 (2001).
  • Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive–compulsive disorder (OCD) and Tourette’s syndrome (TS). Int. J. Neuropsychopharmacol.9(1), 95–100 (2006).
  • Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J. Affect. Disord.102(1–3), 277–280 (2007).
  • Martis B, Alam D, Dowd SM et al. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin. Neurophysiol.114(6), 1125–1132 (2003).
  • McIntosh AM, Semple D, Tasker K et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Res.127(1–2), 9–17 (2004).
  • McLoughlin DM, Mogg A, Eranti S et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol. Assess.11(24), 1–54 (2007).
  • Miniussi C, Bonato C, Bignotti S et al. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression? Clin. Neurophysiol.116(5), 1062–1071 (2005).
  • Mogg A, Pluck G, Eranti SV et al. A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. Psychol. Med.38(3), 323–333 (2008).
  • Mogg A, Purvis R, Eranti S et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr. Res.93(1–3), 221–228 (2007).
  • Moller AL, Hjaltason O, Ivarsson O, Stefansson SB. The effects of repetitive transcranial magnetic stimulation on depressive symptoms and the P(300) event-related potential. Nord J. Psychiatry60(4), 282–285 (2006).
  • Moser DJ, Jorge RE, Manes F, Paradiso S, Benjamin ML, Robinson RG. Improved executive functioning following repetitive transcranial magnetic stimulation. Neurology58(8), 1288–1290 (2002).
  • Mosimann UP, Rihs TA, Engeler J, Fisch H, Schlaepfer TE. Mood effects of repetitive transcranial magnetic stimulation of left prefrontal cortex in healthy volunteers. Psychiatry Res.94(3), 251–256 (2000).
  • Mosimann UP, Schmitt W, Greenberg BD et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Res.126(2), 123–133 (2004).
  • Munchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM. Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology59(11), 1789–1791 (2002).
  • Nahas Z, Bohning DE, Molloy MA, Oustz JA, Risch SC, George MS. Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. J. Clin. Psychiatry60(1), 50–52 (1999).
  • Nahas Z, Kozel FA, Li X, Anderson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord.5(1), 40–47 (2003).
  • Li X, Nahas Z, Anderson B, Kozel FA, George MS. Can left prefrontal rTMS be used as a maintenance treatment for bipolar depression? Depress. Anxiety20(2), 98–100 (2004).
  • O’Connor M, Brenninkmeyer C, Morgan A et al. Relative effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy on mood and memory: a neurocognitive risk–benefit analysis. Cogn. Behav. Neurol.16(2), 118–127 (2003).
  • O’Connor MG, Jerskey BA, Robertson EM, Brenninkmeyer C, Ozdemir E, Leone AP. The effects of repetitive transcranial magnetic stimulation (rTMS) on procedural memory and dysphoric mood in patients with major depressive disorder. Cogn. Behav. Neurol.18(4), 223–227 (2005).
  • O’Reardon JP, Solvason HB, Janicak PG et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol. Psychiatry62(11), 1208–1216 (2007).
  • Okabe S, Ugawa Y, Kanazawa I, Effectiveness of rTMSoPsDSG. 0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared with a realistic sham stimulation in Parkinson’s disease. Mov. Disord.18(4), 382–388 (2003).
  • Padberg F, Schule C, Zwanzger P et al. Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. J. Psychiatr. Res.36(3), 131–135 (2002).
  • Padberg F, Zwanzger P, Keck ME et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology27(4), 638–645 (2002).
  • Padberg F, Zwanzger P, Thoma H et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res.88(3), 163–171 (1999).
  • Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet348(9022), 233–237 (1996).
  • Passard A, Attal N, Benadhira R et al. Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. Brain130(Pt 10), 2661–2670 (2007).
  • Pleger B, Janssen F, Schwenkreis P, Volker B, Maier C, Tegenthoff M. Repetitive transcranial magnetic stimulation of the motor cortex attenuates pain perception in complex regional pain syndrome type I. Neurosci. Lett.356(2), 87–90 (2004).
  • Plewnia C, Reimold M, Najib A, Reischl G, Plontke SK, Gerloff C. Moderate therapeutic efficacy of positron emission tomography-navigated repetitive transcranial magnetic stimulation for chronic tinnitus: a randomised, controlled pilot study. J. Neurol. Neurosurg. Psychiatry78(2), 152–156 (2007).
  • Pomeroy VM, Cloud G, Tallis RC, Donaldson C, Nayak V, Miller S. Transcranial magnetic stimulation and muscle contraction to enhance stroke recovery: a randomized proof-of-principle and feasibility investigation. Neurorehabil. Neural Repair21(6), 509–517 (2007).
  • Poulet E, Brunelin J, Bediou B et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biol. Psychiatry57(2), 188–191 (2005).
  • Poulet E, Brunelin J, Boeuve C et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur. Psychiatry19(6), 382–383 (2004).
  • Prasko J, Paskova B, Zalesky R et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol. Lett.27(3), 327–332 (2006).
  • Prasko J, Zalesky R, Bares M et al. The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol. Lett.28(1), 33–38 (2007).
  • Pridmore S. Rapid transcranial magnetic stimulation and normalization of the dexamethasone suppression test. Psychiatry Clin. Neurosci.53(1), 33–37 (1999).
  • Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. Depress. Anxiety12(3), 118–123 (2000).
  • Prikryl R, Kasparek T, Skotakova S, Ustohal L, Kucerova H, Ceskova E. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr. Res.95(1–3), 151–157 (2007).
  • Rektorova I, Megova S, Bares M, Rektor I. Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients. J. Neurol. Sci.229–230, 157–161 (2005).
  • Rollnik JD, Huber TJ, Mogk H et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport11(18), 4013–4015 (2000).
  • Rosa MA, Gattaz WF, Pascual-Leone A et al. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. Int. J. Neuropsychopharmacol.9(6), 667–676 (2006).
  • Rosa MO, Gattaz WF, Rosa MA et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J. Clin. Psychiatry68(10), 1528–1532 (2007).
  • Rosenberg PB, Mehndiratta RB, Mehndiratta YP, Wamer A, Rosse RB, Balish M. Repetitive transcranial magnetic stimulation treatment of comorbid post-traumatic stress disorder and major depression. J. Neuropsychiatry Clin. Neurosci.14(3), 270–276 (2002).
  • Rossi S, De Capua A, Ulivelli M et al. Effects of repetitive transcranial magnetic stimulation on chronic tinnitus: a randomised, crossover, double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry78(8), 857–863 (2007).
  • Rossi S, Pasqualetti P, Rossini PM et al. Effects of repetitive transcranial magnetic stimulation on movement-related cortical activity in humans. Cereb. Cortex10(8), 802–808 (2000).
  • Rossini D, Lucca A, Zanardi R, Magri L, Smeraldi E. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res.137(1–2), 1–10 (2005).
  • Rumi DO, Gattaz WF, Rigonatti SP et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol. Psychiatry57(2), 162–166 (2005).
  • Saba G, Rocamora JF, Kalalou K et al. Repetitive transcranial magnetic stimulation as an add-on therapy in the treatment of mania: a case series of eight patients. Psychiatry Res.128(2), 199–202 (2004).
  • Saba G, Verdon CM, Kalalou K et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. J. Psychiatr. Res.40(2), 147–152 (2006).
  • Sachdev P, Loo C, Mitchell P, Malhi G. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry Clin. Neurosci.59(3), 354–357 (2005).
  • Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol. Med.37(11), 1645–1649 (2007).
  • Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive–compulsive disorder: a preliminary investigation. J. Clin. Psychiatry62(12), 981–984 (2001).
  • Saitoh Y, Hirayama A, Kishima H et al. Reduction of intractable deafferentation pain due to spinal cord or peripheral lesion by high-frequency repetitive transcranial magnetic stimulation of the primary motor cortex. J. Neurosurg.107(3), 555–559 (2007).
  • Santiago-Rodriguez E, Cardenas-Morales L, Harmony T, Fernandez-Bouzas A, Porras-Kattz E, Hernandez A. Repetitive transcranial magnetic stimulation decreases the number of seizures in patients with focal neocortical epilepsy. Seizure17(8), 677–683 (2008).
  • Sawaki L, Okita T, Fujiwara M, Mizuno K. Effects of subthreshold transcranial magnetic stimulation on choice reaction time and correlation with motor cortical activation. Kobe J. Med. Sci.45(3–4), 165–179 (1999).
  • Schlaghecken F, Munchau A, Bloem BR, Rothwell J, Eimer M. Slow frequency repetitive transcranial magnetic stimulation affects reaction times, but not priming effects, in a masked prime task. Clin. Neurophysiol.114(7), 1272–1277 (2003).
  • Schouten EA, D’Alfonso AA, Nolen WA, De Haan EH, Wijkstra J, Kahn RS. Mood improvement from transcranial magnetic stimulation. Am. J. Psychiatry156(4), 669; author reply 669–670 (1999).
  • Schule C, Zwanzger P, Baghai T et al. Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. J. Psychiatr. Res.37(2), 145–153 (2003).
  • Schutter DJ, Enter D, Hoppenbrouwers SS. High-frequency repetitive transcranial magnetic stimulation to the cerebellum and implicit processing of happy facial expressions. J. Psychiatry Neurosci.34(1), 60–65 (2009).
  • Schutter DJ, van Honk J. Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex. J. Psychiatry Neurosci.31(2), 101–104 (2006).
  • Shiga Y, Tsuda T, Itoyama Y et al. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J. Neurol. Neurosurg. Psychiatry72(1), 124–126 (2002).
  • Shimamoto H, Morimitsu H, Sugita S, Nakahara K, Shigemori M. Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson’s disease. Rinsho Shinkeigaku39(12), 1264–1267 (1999).
  • Shimamoto H, Takasaki K, Shigemori M, Imaizumi T, Ayabe M, Shoji H. Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson’s disease. J. Neurol.248(Suppl. 3), III48–III52 (2001).
  • Siebner HR, Mentschel C, Auer C, Conrad B. Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson’s disease. Neuroreport10(3), 589–594 (1999).
  • Siebner HR, Rossmeier C, Mentschel C, Peinemann A, Conrad B. Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson’s disease. J. Neurol. Sci.178(2), 91–94 (2000).
  • Smith JA, Mennemeier M, Bartel T et al. Repetitive transcranial magnetic stimulation for tinnitus: a pilot study. Laryngoscope117(3), 529–534 (2007).
  • Sole-Padulles C, Bartres-Faz D, Junque C et al. Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study. Cereb. Cortex16(10), 1487–1493 (2006).
  • Speer AM, Repella JD, Figueras S et al. Lack of adverse cognitive effects of 1 Hz and 20 Hz repetitive transcranial magnetic stimulation at 100% of motor threshold over left prefrontal cortex in depression. J. ECT17(4), 259–263 (2001).
  • Stern WM, Tormos JM, Press DZ, Pearlman C, Pascual-Leone A. Antidepressant effects of high and low frequency repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex: a double-blind, randomized, placebo-controlled trial. J. Neuropsychiatry Clin. Neurosci.19(2), 179–186 (2007).
  • Stigsby B, Bohlega S, McLean DR, Al-Kawi MZ. Transcranial magnetic stimulation in Behcet’s disease: a cross-sectional and longitudinal study with 44 patients comparing clinical, neuroradiological, somatosensory and brain-stem auditory evoked potential findings. Clin. Neurophysiol.111(7), 1320–1329 (2000).
  • Strafella AP, Ko JH, Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson’s disease: the contribution of expectation. Neuroimage31(4), 1666–1672 (2006).
  • Szuba MP, O’Reardon JP, Rai AS et al. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression. Biol. Psychiatry50(1), 22–27 (2001).
  • Takeuchi N, Chuma T, Matsuo Y, Watanabe I, Ikoma K. Repetitive transcranial magnetic stimulation of contralesional primary motor cortex improves hand function after stroke. Stroke36(12), 2681–2686 (2005).
  • Tamas RL, Menkes D, El-Mallakh RS. Stimulating research: a prospective, randomized, double-blind, sham-controlled study of slow transcranial magnetic stimulation in depressed bipolar patients. J. Neuropsychiatry Clin. Neurosci.19(2), 198–199 (2007).
  • Tamura Y, Okabe S, Ohnishi T et al. Effects of 1-Hz repetitive transcranial magnetic stimulation on acute pain induced by capsaicin. Pain107(1–2), 107–115 (2004).
  • Tergau F, Naumann U, Paulus W, Steinhoff BJ. Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet353(9171), 2209 (1999).
  • Tergau F, Neumann D, Rosenow F, Nitsche MA, Paulus W, Steinhoff B. Can epilepsies be improved by repetitive transcranial magnetic stimulation? – interim analysis of a controlled study. Suppl. Clin. Neurophysiol.56, 400–405 (2003).
  • Theodore WH, Hunter K, Chen R et al. Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology59(4), 560–562 (2002).
  • Triggs WJ, McCoy KJ, Greer R et al. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol. Psychiatry45(11), 1440–1446 (1999).
  • Turnier-Shea Y, Bruno R, Pridmore S. Daily and spaced treatment with transcranial magnetic stimulation in major depression: a pilot study. Aust. N. Z. J. Psychiatry40(9), 759–763 (2006).
  • Uher R, Yoganathan D, Mogg A et al. Effect of left prefrontal repetitive transcranial magnetic stimulation on food craving. Biol. Psychiatry58(10), 840–842 (2005).
  • Urbach D, Awiszus F. Effects of transcranial magnetic stimulation on results of the twitch interpolation technique. Muscle Nerve23(7), 1125–1128 (2000).
  • Urbach D, Berth A, Awiszus F. Effect of transcranial magnetic stimulation on voluntary activation in patients with quadriceps weakness. Muscle Nerve32(2), 164–169 (2005).
  • Valle AC, Dionisio K, Pitskel NB et al. Low and high frequency repetitive transcranial magnetic stimulation for the treatment of spasticity. Dev. Med. Child Neurol.49(7), 534–538 (2007).
  • van Dijk KD, Most EI, Van Someren EJ, Berendse HW, van der Werf YD. Beneficial effect of transcranial magnetic stimulation on sleep in Parkinson’s disease. Mov. Disord.24(6), 878–884 (2009).
  • Walpoth M, Hoertnagl C, Mangweth-Matzek B et al. Repetitive transcranial magnetic stimulation in bulimia nervosa: preliminary results of a single-centre, randomised, double-blind, sham-controlled trial in female outpatients. Psychother. Psychosom.77(1), 57–60 (2008).
  • Yozbatiran N, Alonso-Alonso M, See J et al. Safety and behavioral effects of high-frequency repetitive transcranial magnetic stimulation in stroke. Stroke40(1), 309–312 (2009).
  • Zanette G, Forgione A, Manganotti P, Fiaschi A, Tamburin S. The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis. J. Neurol. Sci.270(1–2), 18–22 (2008).
  • Zwanzger P, Baghai TC, Padberg F et al. The combined dexamethasone-CRH test before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychoneuroendocrinology28(3), 376–385 (2003).
  • Cook CM, Saucier DM, Thomas AW, Prato FS. Changes in human EEG α activity following exposure to two different pulsed magnetic field sequences. Bioelectromagnetics30(1), 9–20 (2009).
  • Sandyk R. Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson’s disease. Int. J. Neurosci.91(3–4), 189–197 (1997).
  • Sandyk R. Effects of picotesla flux electromagnetic fields on dopaminergic transmission in Tourette’s syndrome. Int. J. Neurosci.84(1–4), 187–194 (1996).
  • Sandyk R. Progressive cognitive improvement in multiple sclerosis from treatment with electromagnetic fields. Int. J. Neurosci.89(1–2), 39–51 (1997).
  • Hallett M. Transcranial magnetic stimulation and the human brain. Nature406(6792), 147–150 (2000).
  • Conca A, Swoboda E, Konig P et al. Clinical impacts of single transcranial magnetic stimulation (sTMS) as an add-on therapy in severely depressed patients under SSRI treatment. Hum. Psychopharmacol.15(6), 429–438 (2000).
  • Flitman SS, Grafman J, Wassermann EM et al. Linguistic processing during repetitive transcranial magnetic stimulation. Neurology50(1), 175–181 (1998).
  • Garcia-Toro M. Acute manic symptomatology during repetitive transcranial magnetic stimulation in a patient with bipolar depression. Br. J. Psychiatry175, 491 (1999).
  • Dolberg OT, Schreiber S, Grunhaus L. Transcranial magnetic stimulation-induced switch into mania: a report of two cases. Biol. Psychiatry49(5), 468–470 (2001).
  • Zwanzger P, Ella R, Keck ME, Rupprecht R, Padberg F. Occurrence of delusions during repetitive transcranial magnetic stimulation (rTMS) in major depression. Biol. Psychiatry51(7), 602–603 (2002).
  • Luborzewski A, Schubert F, Seifert F et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J. Psychiatr. Res.41(7), 606–615 (2007).
  • Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J. Neurosci.21(15), RC157 (2001).
  • Fleischmann A, Prolov K, Abarbanel J, Belmaker RH. The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. Brain Res.699(1), 130–132 (1995).
  • Ji RR, Schlaepfer TE, Aizenman CD et al. Repetitive transcranial magnetic stimulation activates specific regions in rat brain. Proc. Natl Acad. Sci. USA.95(26), 15635–15640 (1998).
  • Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron45(2), 201–206 (2005).
  • Nitsche MA, Fricke K, Henschke U et al. Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. J. Physiol.553(Pt 1), 293–301 (2003).
  • Nitsche MA, Niehaus L, Hoffmann KT et al. MRI study of human brain exposed to weak direct current stimulation of the frontal cortex. Clin. Neurophysiol.115(10), 2419–2423 (2004).
  • Iyer MB, Mattu U, Grafman J, Lomarev M, Sato S, Wassermann EM. Safety and cognitive effect of frontal DC brain polarization in healthy individuals. Neurology64(5), 872–875 (2005).
  • Nitsche MA, Liebetanz D, Antal A, Lang N, Tergau F, Paulus W. Modulation of cortical excitability by weak direct current stimulation – technical, safety and functional aspects. Suppl. Clin. Neurophysiol.56, 255–276 (2003).
  • Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology57(10), 1899–1901 (2001).
  • Liebetanz D, Koch R, Mayenfels S, Konig F, Paulus W, Nitsche MA. Safety limits of cathodal transcranial direct current stimulation in rats. Clin. Neurophysiol.120(6), 1161–1167 (2009).
  • Brakemeier EL, Wilbertz G, Rodax S et al. Patterns of response to repetitive transcranial magnetic stimulation (rTMS) in major depression: replication study in drug-free patients. J. Affect. Disord.108(1–2), 59–70 (2008).
  • Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J. Physiol.527(Pt 3), 633–639 (2000).
  • Liebetanz D, Nitsche MA, Tergau F, Paulus W. Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. Brain125(Pt 10), 2238–2247 (2002).
  • Ardolino G, Bossi B, Barbieri S, Priori A. Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. J. Physiol.568(Pt 2), 653–663 (2005).
  • Dixon D, Brown A, Meenan BJ, Eatock J. Experiences of new product development in the medical device industry. Med. Device Technol.17(3), 20–22 (2006).
  • Martin JL, Murphy E, Crowe JA, Norris BJ. Capturing user requirements in medical device development: the role of ergonomics. Physiol. Meas.27(8), R49–R62 (2006).
  • Kaplan AV, Baim DS, Smith JJ et al. Medical device development: from prototype to regulatory approval. Circulation109(25), 3068–3072 (2004).
  • Buchman AL, Spapperi J, Francuzenko KW, Blakeslee MR, Toffenetti J, Leopold P. Medical device development: design, engineering, testing, and legal issues protection-steps in the process to success. Am. J. Gastroenterol.104(3), 543–545 (2009).
  • Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice. Prentice Hall (Pearson), NJ, USA (2009).
  • Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One4(3), E4824 (2009).
  • Sandyk R. Treatment with electromagnetic fields reverses the long-term clinical course of a patient with chronic progressive multiple sclerosis. Int. J. Neurosci.90(3–4), 177–185 (1997).
  • Nagasako EM, Kalauokalani DA. Ethical aspects of placebo groups in pain trials: lessons from psychiatry. Neurology65(12 Suppl. 4), S59–S65 (2005).
  • Janicak PG, O’Reardon JP, Sampson SM et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J. Clin. Psychiatry69(2), 222–232 (2008).
  • Steinbrook R. Controlling conflict of interest – proposals from the Institute of Medicine. N. Engl. J. Med.360(21), 2160–2163 (2009).
  • Rorsman I, Magnusson M, Johansson BB. Reduction of visuo-spatial neglect with vestibular galvanic stimulation. Scand. J. Rehabil. Med.31(2), 117–124 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.